Loading people...
Deborah Harland is a Partner at SR One, a leading life sciences venture capital firm. She is an experienced investor focused on early-stage biotechnology and healthcare companies.
Deborah Harland invests in early-stage life sciences companies, with a focus on novel therapeutics, digital health, and medical devices. Her interests span innovations poised to transform patient care.
Deborah Harland works as a Partner at SR One, a prominent venture capital firm dedicated to investing in groundbreaking life sciences companies globally.
Deborah Harland is a Partner and Advisor at the transatlantic biotech investment firm SR One, based in London, United Kingdom. Prior to joining SR One in 2005, she held clinical development and medical affairs roles at GlaxoSmithKline and Merrell Dow. She helps manage investments for a firm with over $1 billion in assets under management, recently deploying capital from a $600 million second fund closed in 2023. Throughout her venture capital career, she has directed early-stage therapeutic investments and served on the boards of portfolio companies including Principia Biopharma, Mission Therapeutics, and F2G. Harland earned a doctorate in pharmacology and toxicology alongside a bachelor's degree from the University of Dundee. Her current focus centers on leveraging her extensive clinical research background to build early-stage life sciences companies developing novel medicines and therapeutic platforms.
Deborah Harland serves as a distinguished Partner at SR One, a leading venture capital firm renowned for its strategic investments in the life sciences sector. In this pivotal role, she is instrumental in identifying and nurturing early-stage companies poised to revolutionize healthcare through scientific innovation.
SR One, which spun out from GSK to become an independent venture capital firm, maintains a strong legacy of backing groundbreaking science. Deborah Harland's contributions are central to this mission, as she leverages her extensive scientific and investment expertise to support the next generation of biotech and healthcare leaders. Her investment focus areas are broad yet targeted, encompassing novel therapeutics, cutting-edge digital health solutions, and transformative medical devices. She is particularly adept at recognizing the potential in early-stage ventures that promise significant advancements in patient care and outcomes.
Harland's career background provides a robust foundation for her success in venture capital. She holds a PhD in Molecular Biology from the University of Cambridge, underscoring her deep scientific acumen. Prior to joining SR One, she held significant leadership positions at GSK, including leading the GSK Ventures team. This experience equipped her with invaluable insights into drug discovery, development, and the intricacies of corporate venture capital, allowing her to provide strategic guidance to portfolio companies from a unique vantage point.
Throughout her tenure, Deborah Harland has been actively involved in numerous promising companies, often serving on their boards or as a board observer. Notable investments and board roles include her involvement with companies such as Nodthera, Galecto, Mission Therapeutics, and others within SR One's diverse portfolio. Her active participation helps these companies navigate critical growth stages, from scientific validation to market entry, ensuring they have the resources and strategic direction needed to succeed.
Deborah Harland's dedication to fostering innovation in life sciences makes her a key figure in the venture capital landscape. Her ability to combine rigorous scientific evaluation with astute investment strategy positions her as a vital partner for entrepreneurs aiming to make a lasting impact on global health.
